{"disease":{"id":"acute-uncomplicated-plasmodium-falciparum-malaria","name":"acute uncomplicated plasmodium falciparum malaria"},"drugs":{"marketed":[{"drug_id":"artesunate-amodiaquine-as-aq","indication_name":"Treatment of acute, uncomplicated Plasmodium falciparum malaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"artesunate-amodiaquine (AS-AQ)","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase","drug_class":"Artemisinin derivative + aminoquinoline antimalarial combination","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03167242","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":524,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}